‘Life-changing’ breast cancer drug now available for women with incurable disease in major U-turn by NHS drug chiefs

Thousands of women in England with incurable breast cancer have been granted fresh hope thanks to a drug that extends life for up to three years. 

The approval of the treatment Enhertu for NHS patients is a major U-turn from drug cheifs, who initially ruled it was not good value for money. 

The medicine – which treats a type of breast cancer called HER2-low – has been available in Scotland since 2023, as well as 26 European nations. 

A recent trade deal with the US that affects the UK’s budget for medicines, and changes to the official way value for money is measured are said to have driven the shock decision. 

The move has been described as bittersweet by charities and patients, following several years of relentless campaigning for the drug’s approval, during which time many women died. 

Claire Rowney, Chief Executive of charity Breast Cancer Now, said: ‘Today we can finally say we did it.’

However, she added: ‘We can’t celebrate this momentous decision without remembering the devastating cost of this delay.’

Enhertu, also known as trastuzumab deruxtecan, costs around £10,000 per patient per month in the US but the NHS can negotiate lower drug prices.

Given as an infusion, it is a treatment for patients with an aggressive and fast-growing type of cancer that accounts for roughly half of all cases of the disease.

Findings presented last year at the American Society of Clinical Oncology conference in Chicago showed Enhertu was a ‘highly effective’ drug that should become the first port of call for patients with this form of breast cancer that has spread.

Speaking of today’s approval, Health Secretary Yvette Cooper said: ‘Enhertu can be life-changing, and this recommendation means NHS patients will finally be able to benefit from it.

‘It is a tribute to the campaigners and charities who never stopped pressing for this.’